170 related articles for article (PubMed ID: 38528112)
1. Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M; Espinoza M; Elliott A; Xiu J; Seeber A; El-Deiry W; Antonarakis ES; Graff SL; Hall MJ; Borghaei H; Hoon DSB; Liu SV; Ma PC; McKay RR; Wise-Draper T; Marshall J; Sledge GW; Spetzler D; Zhu H; Hsiehchen D
Nat Cancer; 2024 Mar; ():. PubMed ID: 38528112
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
[TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
4. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
5. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
[TBL] [Abstract][Full Text] [Related]
6. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
[TBL] [Abstract][Full Text] [Related]
7. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Kao C; Powers E; Wu Y; Datto MB; Green MF; Strickler JH; Ready NE; Zhang T; Clarke JM
Clin Lung Cancer; 2021 Nov; 22(6):500-509. PubMed ID: 33972172
[TBL] [Abstract][Full Text] [Related]
10. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
[TBL] [Abstract][Full Text] [Related]
11. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
12. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
13. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
Yarchoan M; Albacker LA; Hopkins AC; Montesion M; Murugesan K; Vithayathil TT; Zaidi N; Azad NS; Laheru DA; Frampton GM; Jaffee EM
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30895946
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer landscape of
Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
Huang D; Zhang F; Tao H; Zhang S; Ma J; Wang J; Liu Z; Cui P; Chen S; Huang Z; Wu Z; Zhao L; Hu Y
Target Oncol; 2020 Feb; 15(1):93-100. PubMed ID: 32052340
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
[TBL] [Abstract][Full Text] [Related]
20. Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.
Burcher KM; Lantz JW; Gavrila E; Abreu A; Burcher JT; Faucheux AT; Xie A; Jackson C; Song AH; Hughes RT; Lycan T; Bunch PM; Furdui CM; Topaloglu U; D'Agostino RB; Zhang W; Porosnicu M
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
